Result: A DNA methylation-based algorithm for diagnosing rheumatoid arthritis

Title:
A DNA methylation-based algorithm for diagnosing rheumatoid arthritis
Source:
Arthritis Research & Therapy, Vol 27, Iss 1, Pp 1-11 (2025)
Publisher Information:
BMC, 2025.
Publication Year:
2025
Collection:
LCC:Diseases of the musculoskeletal system
Document Type:
Academic journal article
File Description:
electronic resource
Language:
English
ISSN:
1478-6362
DOI:
10.1186/s13075-025-03649-x
Accession Number:
edsdoj.13ba8eb45ad84a60b799e273d7dc811e
Database:
Directory of Open Access Journals

Further Information

Abstract Background Rheumatoid arthritis (RA), particularly seronegative disease, is difficult to diagnose early, which can delay treatment initiation. This study aims to develop a binary DNA methylation (DNAm)-based algorithm to diagnose RA. Methods Three datasets (discovery, training, holdout) were constructed from DNAm profiles from 1366 persons (treatment-naïve RA, other inflammatory/autoimmune diseases, healthy individuals). DNAm features that differentiate RA from other inflammatory/autoimmune diseases and healthy individuals were identified using the discovery set. Our classification algorithm was developed using machine learning techniques in the training set. Its diagnostic performance, with and without serological status, was evaluated in the holdout set containing RA cases (15 seropositive, 6 seronegative) and controls (14 other arthritides, 11 healthy individuals). Results Our algorithm included 391 DNAm features. Combined with serological status, it classified RA from controls in the holdout set with the following performance: sensitivity 0.90 [95% CI: 0.70–0.99], specificity 0.88 [95% CI: 0.69–0.97], and AUC 0.96 [95% CI: 0.91–1.00]. Its performance in classifying patients with seronegative RA versus those with other arthritides was: sensitivity 0.83 [95% CI: 0.36–1.00], specificity 0.79 [95% CI: 0.49–0.95], and AUC 0.81 [95% CI: 0.61–1.00]. Conclusions The present DNAm-based classification algorithm may be clinically useful for the early diagnosis of RA, especially in seronegative patients, which currently often poses a diagnostic challenge.